Reginald Tucker-Seeley, MA, ScM, ScD

Reginald Tucker-Seeley, MA, ScM, ScD, concludes the program with advice for caregivers and patients with prostate cancer to maximize the benefit of treatment.

Advice for Patients With Prostate Cancer

This is a synopsis of an Educated Patient Sound Bites series featuring Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute; Rashid K. Sayyid, MD, MSc, of the University of Toronto; and Reginald Tucker-Seeley, MA, ScM, ScD, of ZERO Prostate Cancer.

Dr Reginald Tucker-Seeley emphasizes utilizing the full healthcare team beyond just physicians, including nurses and social workers, to answer questions. Community organizations like ZERO also provide critical patient education and advocacy. He advises fully understanding the care journey ahead of time to avoid surprises. ZERO offers resources mapping out the prostate cancer process.

Dr Tucker-Seeley stresses no one should navigate a cancer diagnosis alone given its life-altering nature. Bringing someone to appointments allows a second set of ears, notetaking, and post-visit discussion to ensure comprehension, as the initial news can overwhelm patients.

In closing, Dr Tucker-Seeley thanks viewers for learning about prostate cancer, hoping they found the patient education program informative.

*Video synopsis is AI-generated and reviewed by CURE editorial staff.

Videos

Practical advice for improving clinical trials to ensure they are more reflective of the overall population of patients with prostate cancer.

Improving Clinical Trials in Prostate Cancer

Dr Reginald Tucker-Seeley discusses decades-long efforts to increase minority representation in trials. He advises against assumptions that minorities lack interest, instead directly asking them to participate. Reviewing inclusion/exclusion criteria to avoid disproportionate exclusion of racial/ethnic groups is also key. Educating minority communities that trials facilitate treatment access and presenting health systems as trustworthy partners can further engagement. Alleviating financial barriers through organizational assistance allows wider participation despite potential travel needs.

Dr Tucker-Seeley adds physicians sometimes erroneously assume patients will decline trials or mistrust recommendations, so patients should inquire about available options. He notes many first turn to “Dr. Google” for information, making patient resources on clinical trials from credible organizations like ZERO vitally important for contextualizing the process and guiding navigation.

In summary, Dr Reginald Tucker-Seeley outlines multifaceted approaches to enhance minority clinical trial participation, including direct outreach, inclusive criteria, financial/logistics support, community education and trust-building, questioning assumptions that drive physician inaction, and providing patient resources from reputable groups.

An experienced public health and cancer researcher offers advice to patients newly diagnosed with prostate cancer and discusses barriers to access to care.

Differences in the Treatment of Patients with Prostate Cancer

Dr Reginald Tucker-Seeley strongly recommends getting second opinions and engaging in shared decision-making to find the right physician fit. He advises replacing doctors unwilling to actively involve patients in treatment discussions. Resources at ZERO Prostate Cancer's website, ZEROcancer.org, provide patient programming and questions to ask during appointments.

On health disparities, Dr Tucker-Seeley states neighborhoods with more ethnic minorities and lower socioeconomics have fewer health-promoting resources, forcing residents to seek care elsewhere. This drives differences in outcomes by place. For example, African American men’s greater prostate cancer diagnosis and mortality rates vary further by geography. Location and accessible resources significantly impact health.

In total, Dr Reginald Tucker-Seeley covers the importance of second opinions, patient engagement/resources in prostate cancer care, and geographic/socioeconomic health disparities influencing outcomes.

Reginald Tucker-Seeley, MA, ScM, ScD, gives an overview of the screening and diagnosis process of prostate cancer.

Screening and Diagnosis of Prostate Cancer

Dr Reginald Tucker-Seeley, MA, ScM, ScD, Vice President of Health Equity at ZERO Prostate Cancer, addresses prostate cancer screening guidelines that can be confusing across age groups. While screening starts at age 50, he notes men at high risk, including African Americans or those with family history, should talk to their primary care physician about screening in their 40s, per ZERO recommendations.

In terms of screening methods, Dr Tucker-Seeley outlines 3 tools endorsed by clinical guidelines – the prostate-specific antigen (PSA) blood test, digital rectal exam, and magnetic resonance imaging (MRI). He acknowledges men may be uncomfortable with the brief digital rectal exam but believes it’s worth enduring to save lives.

In summary, Dr Reginald Tucker-Seeley offers clarification on prostate cancer screening, recommending high-risk men to start discussions in their 40s given family history or genetic risk. He outlines the screening modalities per guidelines – PSA, digital rectal exam, and MRI – arguing the brief discomfort of the exam is justified to enable early detection and save lives.

Reginald Tucker-Seeley, MA, ScM, ScD

Advice for Patients With Prostate Cancer

Improving Clinical Trials in Prostate Cancer

Differences in the Treatment of Patients with Prostate Cancer

Screening and Diagnosis of Prostate Cancer

Latest News